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Summary  Fluoro-2-deoxy-D-glucose  (FDG)-positron  emission  tomography  (PET)
and  PET/computed  tomography  (FDG-PET/CT)  is  regarded  as  a  standard  of  care  in
the  management  of  non-small-cell  lung  carcinoma  (NSCLC)  and  is  a  useful  adjunct  in
the  characterization  of  indeterminate  solitary  lung  nodules  (SLN),  and  pre-treatment
staging  of  NSCLC,  notably  mediastinal  nodal  staging  and  detection  of  remote  metas-
tases.  FDG-PET/CT  has  the  ability  to  assess  locoregional  lymph  node  spread  more
precisely  than  CT,  to  detect  metastatic  lesions  that  would  have  been  missed  on  con-
ventional  imaging  or  are  located  in  difﬁcult  areas,  and  to  help  in  the  differentiation
of  lesions  that  are  equivocal  after  conventional  imaging.  Increasingly  FDG-PET/CT
is  employed  in  radiotherapy  planning,  prediction  of  prognosis  in  terms  of  tumor
response  to  neo-adjuvant,  radiation  and  chemotherapy  treatment.  Evidence  is  accu-
mulating  of  usefulness  of  PET/CT  in  small  cell  lung  cancer.
©  2012  Published  by  Elsevier  Limited  on  behalf  of  King  Saud  Bin  Abdulaziz  University
for  Health  Sciences.  All  rights  reserved.
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ositron  emission  tomography  (PET)  has  dramati-
ally changed  oncological  imaging  practice  by  using variety  of  radionuclides.  PET  enables  in  vivo
haracterization and  measurement  of  biological
rocesses at  cellular  and  molecular  levels.  The  most
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ttp://dx.doi.org/10.1016/j.jiph.2012.09.003eadily  available  radiopharmaceutical  is  2-[18F]-
uoro-2-deoxy-D-glucose  (FDG),  where  ﬂuorine-18
18F) is  a  positron-emitter  giving  rise  to  high-energy
hotons,  and  FDG  is  a glucose  analog  employed
s a tracer  of  glucose  transport  and  metabolism.
he rate  of  cellular  glycolysis  is  reﬂected  by  the
egree  of  FDG  uptake  and  that  can  be  determined
rom imaging  data  with  correction  for  attenuation
f photons  by  body  tissues.  The  relatively  low  speci-
city of  FDG-PET  and  the  difﬁculty  in  localizing  the
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activity  identiﬁed  by  FDG-PET  imaging  have  elicited
efforts to  integrate  FDG-PET  with  other  morpho-
logical imaging  techniques.  Hereby  a  PET/CT  was
introduced  offering  a  combination  of  morphologi-
cal and  molecular/cellular  imaging.  FDG-PET  and
FDG-PET/CT  have  a  better  sensitivity  than  CT  alone
in the  detection  of  locoregional  cancer  spread
and distant  metastases  in  patients  with  NSCLC
and small  cell  lung  cancer  (SCLC).  FDG-PET/CT  is
regarded as  a  standard  of  care  in  the  manage-
ment of  non-small-cell  lung  carcinoma  (NSCLC)  and
small cell  lung  cancer  (SCLC).  It  is  a  useful  adjunct
in the  characterization  of  indeterminate  solitary
pulmonary  nodule  (SPN),  and  pre-treatment  stag-
ing of  NSCLC,  notably  mediastinal  nodal  staging
and detection  of  remote  metastases.  FDG-PET/CT
is more  precise  than  CT  in  its  ability  to  assess
locoregional lymph  node  spread.  It  can  detect
metastatic lesions  that  would  have  been  missed
on conventional  imaging  or  are  located  in  difﬁcult
anatomical  areas,  and  helps  in  the  differentiation
of lesions  that  are  equivocal  after  conventional
imaging. Increasingly  FDG-PET/CT  is  employed  in
radiotherapy  planning,  prediction  of  prognosis  in
terms of  tumor  response  to  neo-adjuvant,  radiation
and chemotherapy  treatment.  Evidence  is  accumu-
lating of  usefulness  of  PET/CT  in  small  cell  lung
cancer.  In  this  review  we  will  discuss  the  role  of
PET/CT  in  the  diagnosis  and  management  of  lung
cancer.
The solitary pulmonary nodule (SPN)
Christensen  et  al.  compared  CT  enhancement  of
SPN vs.  18  FDG.  They  examined  42  SPNs  with  both
CT and  PET  scanning.  CT  was  positive  for  a peak
enhancement  of  more  than  15  HU  in  all  malignant
nodules and  12  benign  nodules  (sensitivity  100%,
speciﬁcity  29%,  PPV  68%  and  NPV  100%).  PET  studies
were positive  by  semi-quantitative  analysis  where
the Standardized  uptake  value  (SUV)  was  greater
than 2.5  in  21  out  of  25  malignant  SPNs  and  3  of  the
17 benign  SPNs  (sensitivity  84%,  speciﬁcity  82%,  PPV
88% and  NPV  78%).  The  study  concluded  that  PET
had much  higher  sensitivity,  and  is  preferable  to
CT in  characterizing  indeterminate  SPNs.  However,
CT remains  useful  and  is  the  ﬁrst  choice  imaging
because of  the  high  NPV,  convenience  and  cost  [1].
Fletcher  et  al.  concluded  in  their  paper  that
deﬁnitely and  probably  benign  SPNs  on  PET  and
CT strongly  predicted  benign  lesions.  However,
such results  were  3 times  more  common  with  PET.
Deﬁnitely  positive  PET  scans  were  much  more  pre-
dictive of  malignancy  than  were  these  results  on
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T.  A  malignant  ﬁnal  diagnosis  was  approximately
0 times  more  likely  than  a  benign  lesion  when  PET
esults were  rated  deﬁnitely  malignant  [2].
A meta-analysis  [3]  found  a consistently  high
ensitivity (80—100%)  of  FDG-PET  for  identifying  a
alignant SPN,  whereas  speciﬁcity  was  lower  and
ore variable  across  studies  (40—100%).
taging lung cancer
ischer  et  al.  conducted  a randomized  study  to
valuate  the  clinical  effect  of  PET—CT  on  preopera-
ive staging  of  NSCLC.  The  study  concluded  that  the
se of  PET—CT  for  preoperative  staging  of  NSCLC
educed both  the  total  number  of  thoracotomies
nd the  number  of  futile  thoracotomies  but  did  not
ffect overall  mortality  [4].
FDG-PET is  a  useful  adjunct  in  NSCLC  TNM  stag-
ng. The  usefulness  of  FDG-PET  mainly  lies  in  nodal
taging and  distant  metastatic  survey.  Deﬁning
alignant involvement  of  mediastinal  lymph  nodes
ventually  determines  operability  of  the  lung  can-
er. Several  meta-analyses  on  the  performance  of
T reported  a pooled  sensitivity  from  51%  to  61%
nd speciﬁcity  from  77%  to  86%,  whereas  PET  had
igniﬁcantly  better  performance  with  a pooled  sen-
itivity from  74%  to  85%  and  speciﬁcity  from  85%  to
1% [5—7].  The  performance  of  PET  was  also  inﬂu-
nced by  the  presence  or  absence  of  lymph  node
nlargement  [8].  When  there  were  enlarged  nodes,
ET’s sensitivity  and  speciﬁcity  operated  at  91%  and
8% respectively.  The  performance  of  imaging  in
ung cancer  is  summarized  in  Table  1.
FDG-PET  is  highly  sensitive  at  identifying  distant
etastases  except  metastases  to  the  brain  owing
o the  fact  that  the  brain  gray  matter  has  high  FDG
ptake normally.  The  rate  of  discovering  unantici-
ated  metastases  by  PET  often  varied  between  10%
nd 20%  of  cases,  and  that  increased  with  the  clini-
al stages,  for  example  in  one  study,  the  rates  were
%, 18%  and  24%  in  patients  with  stage  I, II  and  III
iseases,  respectively  [10,11].
The  impact  of  PET  on  staging  has  shown,  an
p-stage in  16—41%,  and  down-stage  in  6—20%  of
atients  [10,12,13]. Two  multi-centric  trials  have
hown that  the  use  of  PET  could  reduce  unneces-
ary thoracotomies  in  up  to  20%  of  patients  with
uspected  or  proven  NSCLC  [14,15].
The  American  College  of  Chest  Physicians  (ACCP)
linical  Practice  Guidelines  recommends  the  use  of
DG-PET for  mediastinal  and  extra-thoracic  stag-
ng in  patients  with  clinical  stage  IB  to  IIIB  in  lung
ancer being  treated  with  curative  intent.  The  use-
ulness of  PET-CT  is  not  clear  in  clinical  stage  IA.
owever,  it  should  be  considered  in  patients  with
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Table  1  Performance  of  imaging  in  the  staging  of  lung  cancer.
Sensitivity  %  Speciﬁcity  %  NPV  %  PPV  %  References
Initial  evaluation  of  the  mediastinum
CT  47—54  84—88  47—96  30—95  [7,32]
PET  50—89  77—90  50—100  43—100  [7,32]
PET/CT 47—89  60—100  85—99  37.5—100  [33,34,16]
Evaluation  of  extrathoracic  metastases
CT 18 98 89  71  [33]
PET 50—79 75—100 89 75 [33]
PET/CT 92 98 98 89 [33]
Restaging  of  the  mediastinum
CT  59  62  53  66  [34]
PET 71  69  64  75  [34]
PET/CT  77  92  75  93  [34]
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Positive predicted value (PPV); negative predicted value (NPV
linical  1A  lung  cancer  being  treated  with  curative
ntent [7].
Although  PET  is  useful  in  staging  NSCLC,  there  is
 false-positive  rate  in  15—20%  and  false-negatives
ate of  9—28%  [7].  The  false  positive  results  are  pri-
arily due  to  infective  or  inﬂammatory  conditions.
alse negative  results  may  accrue  due  to  low-grade
r slow-growing  tumors,  or  small  lesions.  A  pos-
tive result  from  PET-CT  needs  histopathological
onﬁrmation  as  no  patient  should  be  denied  poten-
ially curative  treatment  based  on  imaging  alone
n other  hand,  patients  with  negative  integrated
ET-CT can  be  operated  upon  without  invasive
ediastinal staging  [8].  The  ACCP  guidelines  [9,16]
ecommend  invasive  conﬁrmation  of  the  radio-
raphic  stage,  regardless  of  whether  a  PET  ﬁnding
s positive  or  negative  in  the  mediastinal  nodes,  for
atients with  (a)  discrete  mediastinal  lymph  node
nlargement,  or  (b)  with  a  radiographically  nor-
al mediastinum  and  a  central  tumor  or  N1  lymph
ode enlargement.  Therefore,  a  positive  PET—CT
erves  as  an  indication  for  further  invasive  testing.
he ACCP  guidelines  also  recommend  histological
onﬁrmation  of  mediastinal  nodes  for  patients  with
 peripheral  clinical  stage  I tumor  with  a  positive
ediastinal nodes  uptake  [9,16].  Guidelines  from
he European  Society  of  Thoracic  Surgeons  [17]
dditionally  recommend  invasive  staging  when  the
rimary tumor  shows  low  FDG  uptake  such  as  in  a
ronchioloalveolar  carcinoma.
Accurate  and  fast  staging  of  small-cell  lung
ancer (SCLC)  is  mandatory  when  choosing  treat-
ent,  but  current  staging  procedures  are  time
onsuming  and  lack  sensitivity.  Fischer  et  al.  con-
ucted the  ﬁrst  prospective  study  on  29  consecutive
atients to  assess  the  role  of  PET/CT  compared  with
T, bone  scintigraphy  and  immunocytochemical
o
a
i
tssessment  of  bone  marrow  biopsy  of  patients  with
CLC. PET/CT  restaged  17%  of  the  patients.  The
ensitivity  for  accurate  staging  of  patients  with
xtensive  disease  was  the  following:  for  standard
taging 79%,  PET  93%  and  PET/CT  93%.  Speciﬁcity
as 100%,  83%  and  100%,  respectively.  The  authors
oncluded  that  FDG-PET/CT  can  simplify  and  per-
aps even  improve  the  accuracy  of  the  current
taging procedure  in  SCLC  [18].
Another  useful  role  of  PET/CT  is  to  guide  biopsy
or difﬁcult  cases  when  CT  fails  to  distinguish  lung
ass from  post-obstructive  pneumonitis.
adiotherapy planning
DG-PET/CT  is  increasingly  used  for  radiotherapy
lanning in  patients  with  non-small-cell  lung  car-
inoma. PET/CT  is  now  preferable  for  radiotherapy
lanning in  NSCLC  rather  than  CT  alone.  Integration
f PET/CT  in  radiotherapy  planning  may  improve
atient outcome  although  studies  that  are  more
linical  are  required  to  arrive  at  a deﬁnite  conclu-
ion [19].  PET/CT  planning  for  target  volumes  in
adiotherapy  of  NSCLC  is  different  from  the  treat-
ent volumes  [20].  The  percentage  of  changes
ecorded, by  PET/CT  ranges  from  27%  to  100%
20]. This  change  may  be  related  to  the  exclusion
f atelectasis  or  inclusion  of  PET-positive  nodes.
arget  volumes  calculated  by  PET/CT  when  com-
ared to  CT  also  greatly  reduce  the  inter-observer
ariability. PET/CT  may  also  provide  improved  ther-
peutic ratio  when  compared  with  conventional
T. Grgic  et  al.  found  signiﬁcantly  better  fusion
f PET  and  planning  CT  can  be  reached  with  PET
cquired  in  the  radiotherapy  position  [21].  The  best
ntra-individual  fusion  results  are  obtained  with
he planning  CT  performed  during  mid-breath  hold
ARS38  
[21].  However,  the  methodology  for  incorporating
PET technique  in  radiotherapy  planning  continues
to be  reﬁned  [22].  Ceresoli  et  al.  in  their  study
suggest that  FDG/PET  should  be  integrated  in  con-
formal radiotherapy  of  mediastinal  elective  node
irradiation  techniques,  as  it  improves  target  volume
delineation  without  a  major  increase  in  predicted
toxicity [23].
Treatment response
A  major  issue  with  treatment  response  and  ulti-
mate prognosis  in  NSCLC  has  until  recently  been
dependent  on  morphologic  information  provided  by
standard chest  radiography  and  CT.  Unfortunately,
these imaging  techniques  cannot  reliably  distin-
guish necrotic  tumor  or  ﬁbrotic  scar  from  residual
tumor  tissue  [24].  Response  evaluation  with  radio-
graphy and  CT  does  not  correlate  well  with
histopathological  response,  and  tumor  response  is
determined  more  by  residual  tumor  aggressiveness
than by  its  size/volume  [25].
Many studies  have  shown  the  sensitivity  and
speciﬁcity of  PET  for  assessing  histopathological
response  of  NSCLC  ranging  between  81%  and  97%,
and 64%  and  100%,  respectively  [26].  Thus,  FDG-
PET/CT  is  regarded  as  a  predictor  of  treatment
response and  a  prognosticator  [27].  FDG-PET/CT
has also  been  used  in  pre-operative  assessment
of prognosis  of  NSCLC  [28].  The  standard  uptake
values (SUV)  of  NSCLC  measured  pre-operatively
correlates  with  tumor  doubling  times  and  on  a mul-
tivariate  analysis,  was  an  independent  predictor  of
disease relapse  and  death  [29,30].  Huang  et  al.
have shown  that  SUV  and  metabolic  tumor  volume
(MTV) changes  from  two  serial  FDG-PET/CT  scans,
before and  after  initial  chemoradiotherapy,  allow
prediction  of  the  treatment  response  in  advanced
NSCLC [31].
Summary: role of PET/CT
• PET/CT  or  PET  are  indicated  for  evaluation  of
mediastinum or  for  metastasis  at  initial  evalu-
ation for  patient  with  resectable  with  curative
intent in  tumor  stage  IA—IIIB  [16,35]
• If  there  is  no  distal  metastasis  then  a  Positive
mediastinal lymph  nodes  by  PET  need  cytological
conﬁrmation by  biopsy  [16,35]• Surgical  treatment  can  be  done  in  operable
patient if  PET  scan  is  negative.  However,  surgi-
cal cytohistological  conﬁrmation  is  necessary  if
[16,35]H.  AL-Jahdali  et  al.
1.  Signiﬁcant  mediastinal  lymph  nodes  enlarge-
ment (smallest  diameter  is  >15  mm  on  CT)
2. A  central  tumor  (middle  1/3  of  the  hemitho-
rax)
3. There  is  suspicion  for  N1
4. The  tumor  has  low  SUVmax
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